Regulators, policymakers and others can more effectively battle the disease by creating incentives to make mpox a more ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

While many of these issues are applicable to other parts of the industry, Cambridge Healthtech Institute (CHI) hosted a panel ...

Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s ...

A lawsuit filed by the Pharmaceutical Research and Manufacturers of America, which claims the Inflation Reduction Act’s ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely ...

Bristol Myers Squibb is continuing its cost-savings measures with layoffs in Lawrenceville, New Jersey. The company announced ...

An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...